473 related articles for article (PubMed ID: 27418274)
41. Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome.
Fang CT; Shau WY; Hsueh PR; Chen YC; Wang JT; Hung CC; Huang LY; Chang SC
J Antimicrob Chemother; 2006 Mar; 57(3):511-9. PubMed ID: 16443700
[TBL] [Abstract][Full Text] [Related]
42. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
Arshad S; Huang V; Hartman P; Perri MB; Moreno D; Zervos MJ
Int J Infect Dis; 2017 Apr; 57():27-31. PubMed ID: 28131729
[TBL] [Abstract][Full Text] [Related]
43. Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients.
Koh YR; Kim KH; Chang CL; Yi J
Ann Lab Med; 2016 May; 36(3):235-43. PubMed ID: 26915612
[TBL] [Abstract][Full Text] [Related]
44. Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chang SC; Hsueh PR
J Antimicrob Chemother; 2014 Jan; 69(1):211-8. PubMed ID: 23997017
[TBL] [Abstract][Full Text] [Related]
45. Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia.
Neuner EA; Casabar E; Reichley R; McKinnon PS
Diagn Microbiol Infect Dis; 2010 Jul; 67(3):228-33. PubMed ID: 20542203
[TBL] [Abstract][Full Text] [Related]
46. Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013.
Coombs GW; Nimmo GR; Daly DA; Le TT; Pearson JC; Tan HL; Robinson JO; Collignon PJ; McLaws ML; Turnidge JD;
Commun Dis Intell Q Rep; 2014 Dec; 38(4):E309-19. PubMed ID: 25631593
[TBL] [Abstract][Full Text] [Related]
47. Determinants of Outcome in Hospitalized Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: Results From National Surveillance in Canada, 2008-2012.
Simor AE; Pelude L; Golding G; Fernandes R; Bryce E; Frenette C; Gravel D; Katz K; McGeer A; Mulvey MR; Smith S; Weiss K;
Infect Control Hosp Epidemiol; 2016 Apr; 37(4):390-7. PubMed ID: 26782274
[TBL] [Abstract][Full Text] [Related]
48. Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacteraemia - A retrospective cohort study.
Talha KM; Ishaq H; Ramesh R; Tariq W; Arshad V; Baddour LM; Sohail MR; Palraj R
Eur J Clin Microbiol Infect Dis; 2021 Jul; 40(7):1503-1510. PubMed ID: 33609261
[TBL] [Abstract][Full Text] [Related]
49. Phenotypic changes of methicillin-resistant Staphylococcus aureus during vancomycin therapy for persistent bacteraemia and related clinical outcome.
Kim T; Kim ES; Park SY; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Chong YP; Kim YS
Eur J Clin Microbiol Infect Dis; 2017 Aug; 36(8):1473-1481. PubMed ID: 28337607
[TBL] [Abstract][Full Text] [Related]
50. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
Paladino JA; Jacobs DM; Shields RK; Taylor J; Bader J; Adelman MH; Wilton GJ; Crane JK; Schentag JJ
Int J Antimicrob Agents; 2014 Dec; 44(6):557-63. PubMed ID: 25282169
[TBL] [Abstract][Full Text] [Related]
51. Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility.
Yang CC; Sy CL; Huang YC; Shie SS; Shu JC; Hsieh PH; Hsiao CH; Chen CJ
Sci Rep; 2018 May; 8(1):7868. PubMed ID: 29777150
[TBL] [Abstract][Full Text] [Related]
52. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia.
Yeh YC; Yeh KM; Lin TY; Chiu SK; Yang YS; Wang YC; Lin JC
J Microbiol Immunol Infect; 2012 Jun; 45(3):214-20. PubMed ID: 22571999
[TBL] [Abstract][Full Text] [Related]
53. Knowing prior methicillin-resistant Staphylococcus aureus (MRSA) infection or colonization status increases the empirical use of glycopeptides in MRSA bacteraemia and may decrease mortality.
Robinson JO; Phillips M; Christiansen KJ; Pearson JC; Coombs GW; Murray RJ
Clin Microbiol Infect; 2014 Jun; 20(6):530-5. PubMed ID: 24224545
[TBL] [Abstract][Full Text] [Related]
54. Clinical features and risk factors of mortality for bacteremia due to community-onset healthcare-associated methicillin-resistant S. aureus.
Lee SC; Lee CW; Shih HJ; Chiou MJ; See LC; Siu LK
Diagn Microbiol Infect Dis; 2013 May; 76(1):86-92. PubMed ID: 23420009
[TBL] [Abstract][Full Text] [Related]
55. Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus.
Wang JL; Chen SY; Wang JT; Wu GH; Chiang WC; Hsueh PR; Chen YC; Chang SC
Clin Infect Dis; 2008 Mar; 46(6):799-806. PubMed ID: 18266610
[TBL] [Abstract][Full Text] [Related]
56. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.
Brown J; Brown K; Forrest A
Antimicrob Agents Chemother; 2012 Feb; 56(2):634-8. PubMed ID: 22123681
[TBL] [Abstract][Full Text] [Related]
57. Predictors and clinical outcomes of persistent methicillin-resistant Staphylococcus aureus bacteremia: a prospective observational study.
Ok HS; Lee HS; Park MJ; Kim KH; Kim BK; Wi YM; Kim JM
Korean J Intern Med; 2013 Nov; 28(6):678-86. PubMed ID: 24307843
[TBL] [Abstract][Full Text] [Related]
58. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
[TBL] [Abstract][Full Text] [Related]
59. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia.
Kim SH; Kim KH; Kim HB; Kim NJ; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2008 Jan; 52(1):192-7. PubMed ID: 17984229
[TBL] [Abstract][Full Text] [Related]
60. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
